Related Experiment Video

Updated: May 26, 2026

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction
06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

The role of c-FLIP splice variants in urothelial tumours

F Ewald1, N Ueffing, L Brockmann

  • 1Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg and Department of Immune Control, Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany.

Cell Death & Disease
|December 23, 2011
PubMed

Insights

Cellular FLICE-inhibitory protein (c-FLIP) protects urothelial carcinoma cells from apoptosis. Targeting the c-FLIP(long) isoform may enhance bladder cancer therapies in resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Death Research

Background:

  • Deregulation of apoptosis, often due to anti-apoptotic protein overexpression, is a hallmark of cancer.
  • Cellular FLICE-inhibitory protein (c-FLIP) is a key regulator of apoptosis, frequently overexpressed in various cancers.
  • Urothelial carcinoma exhibits dysregulated apoptosis, necessitating investigation into c-FLIP's role.

Purpose of the Study:

  • To investigate whether deregulated c-FLIP expression affects apoptosis induction by death ligands in urothelial carcinoma.
  • To elucidate the specific roles of c-FLIP splice variants, c-FLIP(long) (c-FLIP(L)) and c-FLIP(short) (c-FLIP(S)), in urothelial carcinoma.
  • To assess the therapeutic potential of targeting c-FLIP in bladder cancer.

Main Methods:

  • Comparative analysis of c-FLIP isoform expression in urothelial carcinoma tissues and cell lines versus normal tissues.
  • Overexpression studies in urothelial cell lines to assess c-FLIP's impact on apoptosis.
  • RNA interference (RNAi) studies, including isoform-specific RNAi, to determine the functional significance of c-FLIP and its variants.
  • Assessment of apoptosis induction by death ligands CD95L and TRAIL.

Main Results:

  • Diminished expression of the c-FLIP(L) isoform was observed in urothelial carcinoma compared to normal tissues, while c-FLIP(S) levels remained unchanged.
  • Both c-FLIP(L) and c-FLIP(S) contribute to resistance against apoptosis induced by CD95L and TRAIL in urothelial carcinoma cells.
  • Isoform-specific RNAi highlighted the critical role of c-FLIP(L) in conferring resistance.
  • Urothelial carcinoma cells maintain c-FLIP levels sufficient to inhibit extrinsic apoptosis pathway activation.

Conclusions:

  • Urothelial carcinoma cells utilize c-FLIP to evade apoptosis induced by death ligands.
  • The c-FLIP(L) isoform plays a particularly important role in this protective mechanism.
  • Targeting c-FLIP, especially the c-FLIP(L) isoform, represents a promising strategy for enhancing apoptosis-based therapies in bladder cancer, particularly in resistant tumors.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Cell-Free DNA Integrity Analysis in Urine Samples07:58

Cell-Free DNA Integrity Analysis in Urine Samples

Published on: January 5, 2017

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Membrane Asymmetry Regulating Transporters01:19

Membrane Asymmetry Regulating Transporters

Enzymes like flippase, floppase, and scramblase transfer phospholipids from one layer to another in the membrane, thereby affecting membrane asymmetry.
Flippase
Eukaryotic flippases are type-IV P-type ATPases or P4-ATPases belonging to P-type ATPase family proteins that are membrane-bound pumps involved in the ATP-mediated transport of ions and molecules across the membrane. Flippases flip specific phospholipids from the outer to the inner leaflet of a membrane. All P4-ATPases have one...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...